Literature DB >> 1783443

In vitro activity of flomoxef and cefazolin in combination with vancomycin.

C Simon1, M Simon.   

Abstract

207 clinical isolates from strains of patients from the University Children's Hospital of Kiel were investigated for their in vitro activity with the agar dilution method against flomoxef and cefazolin (alone and partially in combination with vancomycin). Staphylococci were also tested with other cephalosporins (cefoxitin, cefamandole, cefotaxime, cefotetan and latamoxef). Flomoxef and cefazolin always acted more vigorously on staphylococci than the other cephalosporins. Resistance of Staphylococcus aureus strains against flomoxef and cefazolin did not occur but was found in 15 and 5 of 98 Staphylococcus epidermidis strains, respectively. Enterococcus faecalis strains were always resistant against both drugs; Streptococcus faecium strains were only moderately sensitive. Combined testing of flomoxef or cefazolin with vancomycin showed synergism in almost all staphylococcal strains. Synergism was stronger when S. epidermidis strains were only weakly sensitive to or resistant against flomoxef and cefazolin in comparison to highly sensitive strains. Flomoxef (or cefazolin) acted synergistically in combination with vancomycin on E. faecalis and S. faecium with the exception of two strains of E. faecalis which showed an additive effect of both drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1783443     DOI: 10.1007/bf01645539

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  4 in total

1.  Studies on multi-antibiotic resistant strains of Staphylococcus aureus.

Authors:  H Chmel; A Person; F Tecson-Tumang
Journal:  Infection       Date:  1982       Impact factor: 3.553

2.  In vitro activity of flomoxef in comparison to other cephalosporins.

Authors:  C Simon; M Simon; C Plieth
Journal:  Infection       Date:  1988 Mar-Apr       Impact factor: 3.553

3.  Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotic.

Authors:  T Tsuji; H Satoh; M Narisada; Y Hamashima; T Yoshida
Journal:  J Antibiot (Tokyo)       Date:  1985-04       Impact factor: 2.649

4.  In vitro activity and beta-lactamase stability of a new difluoro oxacephem, 6315-S.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

  4 in total
  3 in total

Review 1.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

2.  Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.

Authors:  M W Climo; R L Patron; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin.

Authors:  N Aritaka; H Hanaki; L Cui; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.